



Theravance

RECEIVED  
CENTRAL FAX CENTER

FEB 01 2005

Facsimile Cover Sheet

To: Commissioner for Patents  
Attn: Examiner Shibuya, Art Unit 1639  
Company: USPTO  
Fax: (703) 872-9306

From: Jeff Hagenah  
Company: Theravance, Inc.  
Telephone: 650-808-6406  
Fax: 650-808-6078  
Date: February 1, 2005  
# of pages: 3  
(including this page)

If there are any problems in receiving this transmission, please call (650) 808-6406.

---

**Comments:**

Attached is an Interview Summary for U.S. Serial No. 10/015,534.

**Notice of Confidentiality**

The following transmittal contains confidential information intended exclusively for the above-named person. Use, copying, distribution or disclosure of information transmitted in error is strictly prohibited. Please call Theravance, Inc. at the above number if you have received this fax in error, and either destroy or return the enclosures to us.

---

---

PRIVILEGED AND CONFIDENTIAL

---

901 Gateway Blvd., South San Francisco, CA 94080; Tel. (650) 808-6000; Fax (650) 827-8690

**BEST AVAILABLE COPY**

RECEIVED  
CENTRAL FAX CENTER

FEB 01 2005

Certificate of Facsimile Transmission

I hereby certify that this correspondence is being transmitted on the date shown below via facsimile to the Commissioner for Patents, United States Patent and Trademark Office at the facsimile number indicated.

Dated: February 1, 2005

Facsimile Number: (703) 872-9306

By:

Jeffrey A. Hagenuh, Reg. No. 35,175

PATENT

Attorney Docket No. P-011-RC2

Customer No. 27038

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )

CHRISTENSEN et al. )

Group Art Unit: 1639

Application No.: 10/015,534 )

Examiner: Mark Lance Shibuya

Filed: December 13, 2001 )

For: METHODS FOR IDENTIFYING )  
NOVEL MULTIMERIC AGENTS )  
THAT MODULATE RECEPTORS )

**STATEMENT OF SUBSTANCE OF AN INTERVIEW**  
**PURSUANT TO 37 C.F.R. §1.133(b)**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

On January 13, 2005, the undersigned attorney telephoned the Examiner to ask for clarification regarding the restriction requirement/election of species for the above-identified patent application. Specifically, clarification was requested on whether the Examiner was requiring the non-elected subject matter of Claim 36 to be canceled or whether examination would be extended to this subject matter if no prior art is found that anticipates or renders obvious the elected species. The undersigned attorney further questioned whether some intermediate scope of claim would be acceptable if the Examiner was requiring all non-elected subject matter to be canceled. The Examiner indicated that he would consider this issue and call back.

BEST AVAILABLE COPY

Application No. 10/015,534  
Attorney Docket No. P-011-RC2  
Customer No. 27038  
Page 2 of 2

On January 18, 2005, the Examiner telephone the undersigned attorney and suggested that Applicants' amendments take the form of dependent claims that would be considered at the time of examination in order to determine if they constituted an invention that was different from the elected invention.


If there are any questions concerning this paper, please telephone the undersigned attorney at (650) 808-6406.

Respectfully submitted,

THERAVANCE, INC.

Date: February 1, 2005

By:

  
Jeffrey A. Hagenah, Ph.D., Esq.  
Registration No. 35,175  
Telephone No. (650) 808-6406

THERAVANCE, INC.  
901 Gateway Boulevard  
South San Francisco, CA 94080  
Tel: (650) 808-6000  
Fax: (650) 808-6078

BEST AVAILABLE COPY